Editorial
|
|
|
Patients at increased risk of adverse effects
|
|
|
New Products
|
|
|
More assessment needed
|
|
|
|
|
|
Information withheld from patients
|
|
|
|
|
|
|
|
Regulators pander to Big Pharma
|
|
|
|
|
|
Many questions remain unanswered
|
|
|
|
|
|
Comparison with rituximab is needed
|
|
|
|
|
|
|
|
|
Uncertain clinical benefit
|
|
|
|
|
|
|
Encouraging method but uncertainties remain
|
|
|
|
|
|
Just another TNF alpha antagonist
|
|
|
|
|
Adverse Effects
|
|
|
Patients will ultimately benefit from the increased knowledge
|
|
|
|
|
|
Disturbing reports of suicides
|
|
|
|
|
|
Widespread use in spite of the lack of robust evidence
|
|
|
|
|
|
In France, a large number of children are exposed to risks
|
|
|
|
|
|
|
|
Determine the necessity before performing an investigative procedure
|
|
|
|
|
|
Medicines versus lollipops
|
|
|
|
Reviews
|
|
|
Few proven harmful effects
|
|
|
|
|
|
|
|
|
|
|
Results of Accord and Advance trials do not challenge the existing target of 7%
|
|
|
|
|
|
|
|
|